Science News
from research organizations

Guidance molecules: New therapy shows novel therapeutic approach to fighting inflammation

Date:
April 9, 2011
Source:
Charité - Universitätsmedizin Berlin
Summary:
Researchers in Germany have succeeded in finding a new therapeutic approach to certain inflammatory reactions of the body. The approach focuses on guidance molecules, which reduce the body's own immune system to the required level and prevent excessive and damaging inflammation. Possible applications include therapies for inflammation, such as blood poisoning, but also in chronic inflammation and immunological inflammations such as rheumatoid arthritis and organ rejection.
Share:
       
Total shares:  
FULL STORY

Researchers at Charité – Universitätsmedizin Berlin have succeeded in finding a new therapeutic approach to certain inflammatory reactions of the body. The new approach, developed under the leadership of Prof. Dr. Schwab, focuses on guidance molecules, which reduce the body's own immune system to the required level and prevent excessive and damaging inflammation. Possible applications include therapies for inflammation, such as blood poisoning, but also in chronic inflammation and immunological inflammations such as rheumatoid arthritis and organ rejection.

Two types of guidance molecules, the attractive and the repulsive, direct the growth of nerve cells to the actual target. The designation of these molecules ("guidance" molecules) also describes the exclusive function that was previously attributed to them, namely to show the growing nerve fibers the way. The fundamentally new approach to the research of Prof. Dr. Schwab and his team at the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) is the realization that these guidance molecules have an additional hitherto unknown role in the immune system.

The problem with the so-called "excessive" inflammation of the body is that the immune system overreacts and there by aggravates the actual inflammation.  Here the repulsive molecules drive the immune molecules (leukocytes) into the way and thus prevent the inflammation from getting out of control or becoming chronic. The research is published in the current issue of the journal Proceedings of the National Academy of Sciences.

The new approach represents a softer, more specific alternative to the orthodox approaches to the combat of inflammation such as cortisone, due to cortisone’s non-specific effect as well as many associated side effects which pose problems for many patients. Prof. Dr. Schwab is optimistic that through this research, a new effective therapy could be found, which can be effective in the fight against excessive inflammation; due to their fundamentally new understanding of this important aspect of the immune system.


Story Source:

The above story is based on materials provided by Charité - Universitätsmedizin Berlin. Note: Materials may be edited for content and length.


Journal Reference:

  1. V. Mirakaj, S. Brown, S. Laucher, C. Steinl, G. Klein, D. Kohler, T. Skutella, C. Meisel, B. Brommer, P. Rosenberger, J. M. Schwab. Repulsive guidance molecule-A (RGM-A) inhibits leukocyte migration and mitigates inflammation. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1015605108

Cite This Page:

Charité - Universitätsmedizin Berlin. "Guidance molecules: New therapy shows novel therapeutic approach to fighting inflammation." ScienceDaily. ScienceDaily, 9 April 2011. <www.sciencedaily.com/releases/2011/04/110407093234.htm>.
Charité - Universitätsmedizin Berlin. (2011, April 9). Guidance molecules: New therapy shows novel therapeutic approach to fighting inflammation. ScienceDaily. Retrieved May 22, 2015 from www.sciencedaily.com/releases/2011/04/110407093234.htm
Charité - Universitätsmedizin Berlin. "Guidance molecules: New therapy shows novel therapeutic approach to fighting inflammation." ScienceDaily. www.sciencedaily.com/releases/2011/04/110407093234.htm (accessed May 22, 2015).

Share This Page:


Health & Medicine News
May 22, 2015

Latest Headlines
updated 12:56 pm ET